Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 7/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.43 |
| ▸ | KIT | P10721 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.43 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756756 | 0.85 | PTGS2 (0.48) | CDK2KDRBRD4JAK2CDK1 | |
| SCHEMBL13756693 | 0.81 | PTGS2 (0.47) | CDK2KDRBRD4JAK2CDK1 | |
| SCHEMBL13756697 | 0.80 | CSF1R (0.41) | CDK2BRD4JAK2CDK4 | |
| SCHEMBL13756752 | 0.80 | BRD4 (0.49) | BRD4STK17ASTK17B | |
| SCHEMBL13756768 | 0.80 | NUAK1 (0.44) | CDK2BRD4JAK2CDK1AURKA | |
| SCHEMBL13756691 | 0.79 | AURKA (0.54) | BRD4JAK2FLT3AURKACDK4 | |
| SCHEMBL13756753 | 0.79 | FGFR4 (0.50) | KDRJAK2FLT3CDK5CDK5R1 | |
| SCHEMBL13756834 | 0.79 | CDK2 (0.43) | CDK2JAK2CDK1AURKACCNB1 | |
| SCHEMBL13756755 | 0.79 | PTK2 (0.48) | CDK2KDRBRD4CDK5CDK5R1 | |
| SCHEMBL13756846 | 0.79 | CDK2 (0.44) | CDK2JAK2CDK1FLT3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CDK2 77/4885KDR 1103/4885BRD4 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.